{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:52:06Z","timestamp":1768866726736,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>As more children survive acute myeloid leukemia (AML) it is increasingly important to assess possible late effects of the intensive treatment. Hearing loss has only sporadically been reported in survivors of childhood AML. We assessed hearing status in survivors of childhood AML treated with chemotherapy alone according to 3 consecutive NOPHO-AML trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Procedure:<\/jats:title>\n            <jats:p>A population-based cohort of children treated according to the NOPHO-AML-84, NOPHO-AML-88, and NOPHO-AML-93 trials included 137 eligible survivors among whom 101 (74%) completed a questionnaire and 99 (72%) had otologic and audiologic examination performed including otoscopy (72%), pure tone audiometry (70%), and tympanometry (60%). Eighty-four of 93 (90%) eligible sibling controls completed a similar questionnaire.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>At a median of 11 years (range, 4 to 25) after diagnosis, hearing disorders were rare in survivors of childhood AML and in sibling controls, with no significant differences. None had severe or profound hearing loss diagnosed at audiometry. Audiometry detected a subclinical hearing loss ranging from slight to moderate in 19% of the survivors, 5% had low-frequency hearing loss, and 17% had high-frequency hearing loss.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The frequency of hearing disorders was low, and hearing thresholds in survivors of childhood AML were similar to background populations of comparable age.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000001302","type":"journal-article","created":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T02:47:07Z","timestamp":1544842027000},"page":"e12-e17","source":"Crossref","is-referenced-by-count":1,"title":["Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study"],"prefix":"10.1097","volume":"41","author":[{"given":"Anne-Sofie","family":"Skou","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen \u00d8.","family":"Olsen","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Head and Neck Surgery, and Audiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars H.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Head and Neck Surgery, and Audiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Glosli","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Jahnukainen","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Jarfelt","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, The Queen Silvia Children\u2019s Hospital, Gothenburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gu\u00f0mundur K.","family":"J\u00f3nmundsson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Landspitalinn University Hospital, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Malmros","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Karolinska University Hospital"},{"name":"Department of Women\u00b4s and Children\u2019s Health, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[{"name":"Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Hasle","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1096-911X(199903)32:3<163::AID-MPO1>3.0.CO;2-#","article-title":"Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia","volume":"32","author":"Leahey","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1200\/JCO.1994.12.5.916","article-title":"Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood","volume":"12","author":"Liesner","year":"1994","journal-title":"J Clin Oncol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1200\/JCO.2000.18.18.3273","article-title":"Late effects of treatment in survivors of childhood acute myeloid leukemia","volume":"18","author":"Leung","year":"2000","journal-title":"J Clin Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.1997.15.6.2238","article-title":"Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation\u2014a report from the societe francaise de greffe de moelle","volume":"15","author":"Michel","year":"1997","journal-title":"J Clin Oncol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/pbc.23025","article-title":"Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study","volume":"57","author":"Whelan","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1542\/peds.2009-1597","article-title":"Auditory late effects of childhood cancer therapy: a report from the children\u2019s oncology group","volume":"125","author":"Grewal","year":"2010","journal-title":"Pediatrics"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/pbc.24448","article-title":"High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine","volume":"60","author":"Johannsen","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/cncr.23405","article-title":"Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the childhood cancer survivor study","volume":"112","author":"Mulrooney","year":"2008","journal-title":"Cancer"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.leu.2401906","article-title":"Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects","volume":"14","author":"Arnaout","year":"2000","journal-title":"Leukemia"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/pbc.22931","article-title":"Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study","volume":"57","author":"Molgaard-Hansen","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1002\/pbc.24715","article-title":"Pubertal development and fertility in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study","volume":"60","author":"Molgaard-Hansen","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/pbc.25069","article-title":"Renal, gastrointestinal, and hepatic late effects in survivors of childhood acute myeloid leukemia treated with chemotherapy only\u2014a NOPHO-AML study","volume":"61","author":"Skou","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"e20170619","DOI":"10.1542\/peds.2017-0619","article-title":"Trends in hearing loss among adolescents","volume":"140","author":"Barrett","year":"2017","journal-title":"Pediatrics"},{"key":"R15-20230918","first-page":"171","article-title":"The pure-tone hearing thresholds of otologically healthy 14-year-old children","volume":"40","author":"Rahko-Laitila","year":"2001","journal-title":"Audiology"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/sj.leu.2403962","article-title":"Long-term results in children with AML: NOPHO-AML study group\u2014report of three consecutive trials","volume":"19","author":"Lie","year":"2005","journal-title":"Leukemia"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/cncr.29779","article-title":"Ototoxicity and cancer therapy","volume":"122","author":"Landier","year":"2016","journal-title":"Cancer"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/pbc.24631","article-title":"Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides","volume":"60","author":"Chen","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1200\/JCO.2015.65.8591","article-title":"Strategies for empiric management of pediatric fever and neutropenia in patients with cancer and hematopoietic stem-cell transplantation recipients: A systematic review of randomized trials","volume":"34","author":"Robinson","year":"2016","journal-title":"J Clin Oncol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/adc.2009.158220","article-title":"Aminoglycoside-induced deafness during treatment of acute leukaemia","volume":"95","author":"Bitner-Glindzicz","year":"2010","journal-title":"Arch Dis Child"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jpeds.2013.10.024","article-title":"Mitochondrial 12S ribosomal RNA A1555G mutation associated with cardiomyopathy and hearing loss following high-dose chemotherapy and repeated aminoglycoside exposure","volume":"164","author":"Skou","year":"2014","journal-title":"J Pediatr"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201901000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:41:31Z","timestamp":1695012091000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201901000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001302","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}